{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:24:56Z","timestamp":1707524696454},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,31]]},"DOI":"10.7759\/cureus.30905","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T12:56:25Z","timestamp":1667220985000},"source":"Crossref","is-referenced-by-count":2,"title":["Guillain-Barre Syndrome After COVID-19 Vaccination: A Secondary Analysis of Domestic Safety Data by the Japanese Government"],"prefix":"10.7759","author":[{"given":"Yudai","family":"Kaneda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanao","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uiri","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanari","family":"Inada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Senoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Fujieda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Tanimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"World Health Organization. WHO coronavirus (COVID-19) dashboard. (2022). Accessed. 2022 March 20: https:\/\/covid19.who.int\/table."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.24315","article-title":"Winter of Omicron\u2014the evolving COVID-19 pandemic","volume":"327","author":"Del Rio C","year":"2022","unstructured":"Del Rio C, Omer SB, Malani PN. Winter of Omicron\u2014the evolving COVID-19 pandemic. JAMA. 2022, 327:319-20. 10.1001\/jama.2021.24315","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202102_24877","article-title":"COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer\/BioNTech and Moderna Vaccines","volume":"25","author":"Meo SA","year":"2021","unstructured":"Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer\/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci. 2021, 25:1663-9. 10.26355\/eurrev_202102_24877","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taab090","article-title":"High anaphylaxis rates following vaccination with the Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers: a secondary analysis of initial post-approval safety data","volume":"28","author":"Hashimoto T","year":"2021","unstructured":"Hashimoto T, Ozaki A, Bhandari D, Sawano T, Sah R, Tanimoto T. High anaphylaxis rates following vaccination with the Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers: a secondary analysis of initial post-approval safety data. J Travel Med. 2021, 28:10.1093\/jtm\/taab090","journal-title":"J Travel Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200932040-00005","article-title":"Vaccines and Guillain-Barr\u00e9 syndrome","volume":"32","author":"Haber P","year":"2009","unstructured":"Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and Guillain-Barr\u00e9 syndrome. Drug Saf. 2009, 32:309-23. 10.2165\/00002018-200932040-00005","journal-title":"Drug Saf"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05849-0","article-title":"Guillain-Barr\u00e9 syndrome associated with BNT162b2 COVID vaccination: a first case report from South Korea","volume":"43","author":"Kim N","year":"2022","unstructured":"Kim N, Kim JH, Park JS. Guillain-Barr\u00e9 syndrome associated with BNT162b2 COVID vaccination: a first case report from South Korea. Neurol Sci. 2022, 43:1491-3. 10.1007\/s10072-021-05849-0","journal-title":"Neurol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.13426","article-title":"Neurological complications of COVID-19: Guillain-Barre syndrome following Pfizer COVID-19 vaccine","volume":"13","author":"Waheed S","year":"2021","unstructured":"Waheed S, Bayas A, Hindi F, Rizvi Z, Espinosa PS. Neurological complications of COVID-19: Guillain-Barre syndrome following Pfizer COVID-19 vaccine. Cureus. 2021, 13:e13426. 10.7759\/cureus.13426","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577719","article-title":"AstraZeneca COVID-19 vaccine and Guillain-Barr\u00e9 Syndrome in Tasmania: a causal link?","volume":"360","author":"Oo WM","year":"2021","unstructured":"Oo WM, Giri P, de Souza A. AstraZeneca COVID-19 vaccine and Guillain-Barr\u00e9 Syndrome in Tasmania: a causal link?. J Neuroimmunol. 2021, 360:577719. 10.1016\/j.jneuroim.2021.577719","journal-title":"J Neuroimmunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/20009666.2021.1954284","article-title":"A case of Guillain-Barre syndrome following Pfizer COVID-19 vaccine","volume":"11","author":"Rao SJ","year":"2021","unstructured":"Rao SJ, Khurana S, Murthy G, Dawson ET, Jazebi N, Haas CJ. A case of Guillain-Barre syndrome following Pfizer COVID-19 vaccine. J Community Hosp Intern Med Perspect. 2021, 11:597-600. 10.1080\/20009666.2021.1954284","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2021.102540","article-title":"Post-COVID-19 vaccine Guillain-Barr\u00e9 syndrome; first reported case from Qatar","volume":"67","author":"Razok A","year":"2021","unstructured":"Razok A, Shams A, Almeer A, Zahid M. Post-COVID-19 vaccine Guillain-Barr\u00e9 syndrome; first reported case from Qatar. Ann Med Surg (Lond). 2021, 67:102540. 10.1016\/j.amsu.2021.102540","journal-title":"Ann Med Surg (Lond)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2021.106887","article-title":"Guillain-Barr\u00e9\u00a0syndrome after AstraZeneca COVID-19-vaccination: a causal or casual association?","volume":"208","author":"Introna A","year":"2021","unstructured":"Introna A, Caputo F, Santoro C, Guerra T, Ucci M, Mezzapesa DM, Trojano M. Guillain-Barr\u00e9\u00a0syndrome after AstraZeneca COVID-19-vaccination: a causal or casual association?. Clin Neurol Neurosurg. 2021, 208:106887. 10.1016\/j.clineuro.2021.106887","journal-title":"Clin Neurol Neurosurg"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.32598\/bcn.2021.3565.1","article-title":"Guillain-Barre syndrome and COVID-19 vaccine: a report of nine patients","volume":"12","author":"Karimi N","year":"2021","unstructured":"Karimi N, Boostani R, Fatehi F, et al.. Guillain-Barre syndrome and COVID-19 vaccine: a report of nine patients. Basic Clin Neurosci. 2021, 12:703-10. 10.32598\/bcn.2021.3565.1","journal-title":"Basic Clin Neurosci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcac102","article-title":"Guillain-Barr\u00e9 syndrome after BNT162b2 (Pfizer-BioNTec) vaccination","volume":"115","author":"Takahashi K","year":"2022","unstructured":"Takahashi K, Tomoda Y, Kadena S, Kanbayashi T, Kobayashi S, Kato R. Guillain-Barr\u00e9 syndrome after BNT162b2 (Pfizer-BioNTec) vaccination. QJM. 2022, 115:331-3. 10.1093\/qjmed\/hcac102","journal-title":"QJM"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-244125","article-title":"Guillain-Barr\u00e9 syndrome after COVID-19 vaccination","volume":"14","author":"McKean N","year":"2021","unstructured":"McKean N, Chircop C. Guillain-Barr\u00e9 syndrome after COVID-19 vaccination. BMJ Case Rep. 2021, 14:e244125. 10.1136\/bcr-2021-244125","journal-title":"BMJ Case Rep"},{"key":"ref15","unstructured":"Prime Minister's Office of Japan. COVID-19 vaccines 2022. (2022). Accessed. 2022 March 20: https:\/\/japan.kantei.go.jp\/ongoingtopics\/vaccine.html."},{"key":"ref16","unstructured":"Efficacy and safety of the COVID-19 vaccine [In Japanese]. (2022). Accessed. 2022 April 25: https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/vaccine_yuukousei_anzensei.html."},{"key":"ref17","unstructured":"Development status [In Japanese]. (2022). Accessed. 2022 March 20: https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000121431_00223.html."},{"key":"ref18","unstructured":"About the COVID-19 vaccine [In Japanese]. (2022). Accessed. 2022 March 20: https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/vaccine_00184.html."},{"key":"ref19","unstructured":"Vaccination data [In Japanese]. (2022). Accessed. 2022 March 20: https:\/\/www.kantei.go.jp\/jp\/content\/vaccination_data5.pdf."},{"key":"ref20","unstructured":"Reports of suspected adverse reactions to the COVID-19 vaccine [In Japanese]. (2022). Accessed. 2022 May 8: https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/vaccine_hukuhannou-utagai-houkoku.html."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.8879","article-title":"Incidence of Guillain-Barr\u00e9 syndrome after COVID-19 vaccination in the Vaccine Safety Datalink","volume":"5","author":"Hanson KE","year":"2022","unstructured":"Hanson KE, Goddard K, Lewis N, et al.. Incidence of Guillain-Barr\u00e9 syndrome after COVID-19 vaccination in the Vaccine Safety Datalink. JAMA Netw Open. 2022, 5:e228879. 10.1001\/jamanetworkopen.2022.8879","journal-title":"JAMA Netw Open"},{"key":"ref22","unstructured":"Selected adverse events reported after COVID-19 vaccination. (2022). Accessed. 2022 April 18: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/safety\/adverse-events.html."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000000929","article-title":"Guillain-Barr\u00e9 syndrome","volume":"26","author":"Sheikh KA","year":"2020","unstructured":"Sheikh KA. Guillain-Barr\u00e9 syndrome. Continuum (Minneap Minn). 2020, 26:1184-204. 10.1212\/CON.0000000000000929","journal-title":"Continuum (Minneap Minn)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1114525","article-title":"Guillain-Barr\u00e9 syndrome","volume":"366","author":"Yuki N","year":"2012","unstructured":"Yuki N, Hartung HP. Guillain-Barr\u00e9 syndrome. N Engl J Med. 2012, 366:2294-304. 10.1056\/NEJMra1114525","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.04.066","article-title":"Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines","volume":"39","author":"Somiya M","year":"2021","unstructured":"Somiya M, Mine S, Yasukawa K, Ikeda S. Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines. Vaccine. 2021, 39:3313-4. 10.1016\/j.vaccine.2021.04.066","journal-title":"Vaccine"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1967","article-title":"Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US-December 14, 2020-January 18, 2021","volume":"325","author":"Shimabukuro TT","year":"2021","unstructured":"Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US-December 14, 2020-January 18, 2021. JAMA. 2021, 325:1101-2. 10.1001\/jama.2021.1967","journal-title":"JAMA"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3976","article-title":"Acute allergic reactions to mRNA COVID-19 vaccines","volume":"325","author":"Blumenthal KG","year":"2021","unstructured":"Blumenthal KG, Robinson LB, Camargo CA Jr, Shenoy ES, Banerji A, Landman AB, Wickner P. Acute allergic reactions to mRNA COVID-19 vaccines. JAMA. 2021, 325:1562-5. 10.1001\/jama.2021.3976","journal-title":"JAMA"},{"key":"ref28","unstructured":"Third municipal briefing (February 17, 2021) [In Japanese]. (2022). Accessed. 2022 March 20: https:\/\/www.city.chiba.jp\/hokenfukushi\/iryoeisei\/seisaku\/documents\/fukuhannnou_utagai.pdf."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for adverse events after COVID-19 mRNA vaccination","volume":"326","author":"Klein NP","year":"2021","unstructured":"Klein NP, Lewis N, Goddard K, et al.. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. 2021, 326:1390-9. 10.1001\/jama.2021.15072","journal-title":"JAMA"},{"key":"ref30","unstructured":"Guillain-Barre Fisher Syndrome guidelines 2013. (2013). Accessed. 2022 March 20: https:\/\/www.neurology-jp.org\/guidelinem\/gbs.html."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181e07d14","article-title":"Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study","volume":"74","author":"Ruts L","year":"2010","unstructured":"Ruts L, Drenthen J, Jacobs BC, van Doorn PA. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology. 2010, 74:1680-6. 10.1212\/WNL.0b013e3181e07d14","journal-title":"Neurology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/122872-guillain-barre-syndrome-after-covid-19-vaccination-a-secondary-analysis-of-domestic-safety-data-by-the-japanese-government","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:48:01Z","timestamp":1707508081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/122872-guillain-barre-syndrome-after-covid-19-vaccination-a-secondary-analysis-of-domestic-safety-data-by-the-japanese-government"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,31]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.30905","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,31]]}}}